OralParenteralTherapeutic flag Cosmetic cross-reference

Etidronic Acid

CAS 2809-21-4

Etidronic Acid (CAS 2809-21-4) is a Phase 4 pharmaceutical compound with 1 bioactivity target and 26 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Etidronic Acid

CAS Number

2809-21-4

UNII

M2F465ROXU

InChIKey

DBVJJBKOTRCVKF-UHFFFAOYSA-N

ChEMBL ID

CHEMBL871

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

natural productoralparenteraltherapeutic flag

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)

Approved or marketed human pharmaceutical use is represented in the source phase field.

ChEMBL CHEMBL871 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 6 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	AC50	30000 nM	30	-
-	Potency	22476.18 nM	10	-
-	IC50	47488.155 nM	3	-
-	EC50	5165 nM	2	-
-	Ki	3 nM	1	-
Type IV secretion-like conjugative transfer relaxase protein TraI Unclassified	Ki	8.52	-	Escherichia coli

SOURCE DrugCentral 10 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PT	Drug AE	LLR	MedDRA
Venous pressure jugular increased	16	92.425	10047240
Kyphosis	18	88.317	10023509
Atypical femur fracture	19	86.538	10070884
Rectal prolapse	16	83.521	10038077
Lip blister	14	66.697	10049307
Bundle branch block left	17	62.055	10006580
Upper-airway cough syndrome	16	55.048	10070488
Blood test abnormal	17	52.831	10061016
Osteonecrosis of jaw	20	49.116	10064658
Hiatus hernia	17	48.241	10020028

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE PharmGKB 3 phenotype rows

Pharmacogenomics

Drug-gene phenotype annotations and evidence levels from PharmGKB-mapped rows.

COL1A1 (PA35041) rs1800012

Genotypes AA + AC are associated with decreased response to etidronic acid in people with Bone Diseases, Metabolic as compared to genotype CC.

Evidence: -; PMID 11907712

VDR (PA37301) rs1544410

Genotype TT is associated with increased Mean spinal bone mineral density changes when treated with calcium and etidronic acid in people with Osteoporosis, Postmenopausal as compared to genotype CC.

Evidence: -; PMID 10692979

IL1B rs16944

Osteitis Deformans

Evidence: 3; PMID 1

SOURCE SIDER 80 side-effect rows

Side Effects

SIDER side-effect terms mapped to the drug or same-CAS compound identity.

Side Effect	Drug Name	MedDRA Type	Concept ID
Abdominal pain	etidronate	LLT	C0000737
Abdominal pain	etidronate	PT	C0000737
Agranulocytosis	etidronate	LLT	C0001824
Agranulocytosis	etidronate	PT	C0001824
Alopecia	etidronate	LLT	C0002170
Alopecia	etidronate	PT	C0002170
Amnesia	etidronate	LLT	C0002622
Amnesia	etidronate	PT	C0002622
Anaemia	etidronate	LLT	C0002871
Anaemia	etidronate	PT	C0002871
Angioedema	etidronate	LLT	C0002994
Angioedema	etidronate	PT	C0002994
Arthralgia	etidronate	LLT	C0003862
Arthralgia	etidronate	PT	C0003862
Arthritis	etidronate	LLT	C0003864
Arthritis	etidronate	PT	C0003864
Arthropathy	etidronate	LLT	C0022408
Arthropathy	etidronate	PT	C0022408
Asthma	etidronate	PT	C0004096
Bone pain	etidronate	LLT	C0151825
Bone pain	etidronate	PT	C0151825
Burning tongue	etidronate	LLT	C0241426
Confusional state	etidronate	LLT	C0009676
Confusional state	etidronate	PT	C0009676
Constipation	etidronate	LLT	C0009806
Constipation	etidronate	PT	C0009806
Cramps of lower extremities	etidronate	LLT	C0023218
Dermatitis	etidronate	PT	C0011603
Diarrhoea	etidronate	LLT	C0011991
Diarrhoea	etidronate	PT	C0011991
Discomfort	etidronate	LLT	C0234215
Discomfort	etidronate	PT	C0234215
Dyspepsia	etidronate	LLT	C0013395
Dyspepsia	etidronate	PT	C0013395
Ectopic ossification	etidronate	LLT	C0029396
Erythema	etidronate	LLT	C0041834
Erythema	etidronate	PT	C0041834
Erythema multiforme	etidronate	LLT	C0014742
Erythema multiforme	etidronate	PT	C0014742
Erythema multiforme	etidronate	PT	C0014742
Exacerbation of asthma	etidronate	LLT	C0349790
Extraskeletal ossification	etidronate	PT	C0334040
Feeling abnormal	etidronate	PT	C1443060
Flatulence	etidronate	LLT	C0016204
Flatulence	etidronate	PT	C0016204
Fracture	etidronate	LLT	C0016658
Fracture	etidronate	PT	C0016658
Gastritis	etidronate	LLT	C0017152
Gastritis	etidronate	PT	C0017152
Gastrointestinal pain	etidronate	PT	C0687713
Glossitis	etidronate	LLT	C0017675
Glossitis	etidronate	PT	C0017675
Glossodynia	etidronate	PT	C0017672
Hallucination	etidronate	LLT	C0018524
Hallucination	etidronate	PT	C0018524
Headache	etidronate	LLT	C0018681
Headache	etidronate	PT	C0018681
Hypercalcaemia of malignancy	etidronate	LLT	C0149911
Hypercalcaemia of malignancy	etidronate	PT	C0149911
Hypersensitivity	etidronate	LLT	C0020517
Hypersensitivity	etidronate	PT	C0020517
Infection	etidronate	LLT	C0009450
Infection	etidronate	PT	C0009450
Leukaemia	etidronate	LLT	C0023418
Leukaemia	etidronate	PT	C0023418
Leukopenia	etidronate	LLT	C0023530
Leukopenia	etidronate	PT	C0023530
Multiple fractures	etidronate	PT	C0016655
Muscle spasms	etidronate	PT	C0037763
Musculoskeletal discomfort	etidronate	PT	C0948594
Nausea	etidronate	LLT	C0027497
Nausea	etidronate	PT	C0027497
Neuropathy peripheral	etidronate	LLT	C0031117
Neuropathy peripheral	etidronate	PT	C0031117
Oesophagitis	etidronate	LLT	C0014868
Oesophagitis	etidronate	PT	C0014868
Oral disorder	etidronate	LLT	C0026636
Oral disorder	etidronate	PT	C0026636
Osteoarthritis	etidronate	PT	C0029408
Osteoarthritis	etidronate	LLT	C0029408

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Etidronic Acid used for in pharmaceutical contexts?

Etidronic Acid (CAS 2809-21-4) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Etidronic Acid?

Etidronic Acid has 26 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Venous pressure jugular increased, Kyphosis, Atypical femur fracture, Rectal prolapse, Lip blister. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Etidronic Acid also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Etidronic Acid with EU status "restricted".

What clinical phase is Etidronic Acid in?

Etidronic Acid is rendered with ChEMBL max phase 4 (approved).

What bioactivity targets are documented for Etidronic Acid?

Etidronic Acid has 6 bioactivity rows in this page query. Rendered target entries include Type IV secretion-like conjugative transfer relaxase protein TraI.